{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:41:15Z","timestamp":1787161275745,"version":"build-2736575974"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02060","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:26:52Z","timestamp":1566952012000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Immunotherapy in People With HIV and Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Camille E.","family":"Puronen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cncr.32158","article-title":"Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base","volume":"125","author":"Coghill","year":"2019","journal-title":"Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/cid\/ciy508","article-title":"Cessation of cigarette smoking and the impact on cancer incidence in human immunodeficiency virus-infected persons: the data collection on adverse events of anti-HIV drugs study","volume":"68","author":"Shepherd","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/QAI.0000000000001842","article-title":"Reduced cancer survival among adults with HIV and AIDS-defining illnesses despite no difference in cancer stage at diagnosis","volume":"79","author":"Grover","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"ciz329","DOI":"10.1093\/cid\/ciz329","article-title":"Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada","volume":"2019","author":"Hernandez-Ramirez","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2352-3018(18)30360-6","article-title":"Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study","volume":"6","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2019","journal-title":"Lancet HIV"},{"key":"B6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","article-title":"Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992\u20132003","volume":"148","author":"Patel","year":"2008","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/QAD.0000000000000922","article-title":"Prevalence of non-HIV cancer risk factors in persons living with HIV\/AIDS: a meta-analysis","volume":"30","author":"Park","year":"2016","journal-title":"AIDS"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/cid\/ciu076","article-title":"HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy","volume":"58","author":"Achenbach","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study","volume":"103","author":"Franceschi","year":"2010","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570162X17666190327153038","article-title":"The pattern of non-AIDS-defining cancers in the HIV population: epidemiology, risk factors and prognosis. A review","volume":"17","author":"Franzetti","year":"2019","journal-title":"Curr HIV Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1186\/s12885-018-4963-8","article-title":"Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study","volume":"18","author":"Nagata","year":"2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/1471-2334-13-471","article-title":"Non-AIDS defining cancers in the D:A:D Study\u2013time trends and predictors of survival: a cohort study","volume":"13","author":"Worm","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e25219","DOI":"10.1002\/jia2.25219","article-title":"Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific","volume":"22","author":"Jung","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","article-title":"Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: a systematic review","volume":"8","author":"Cobucci","year":"2015","journal-title":"J Infect Public Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cell.2010.11.001","article-title":"Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue","volume":"143","author":"Doitsh","year":"2010","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/QAD.0000000000000314","article-title":"Programmed death-1 expression on CD4? and CD8? T cells in treated and untreated HIV disease","volume":"28","author":"Cockerham","year":"2014","journal-title":"AIDS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/infdis\/jix039","article-title":"Human immunodeficiency virus persistence and T-cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy","volume":"215","author":"Khoury","year":"2017","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.4049\/jimmunol.1701551","article-title":"Immune checkpoint blockade restores HIV-specific CD4 T cell help for NK cells","volume":"201","author":"Porichis","year":"2018","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2011-11-395384","article-title":"Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists","volume":"119","author":"Baum","year":"2012","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nm0597-533","article-title":"HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies","volume":"3","author":"Connors","year":"1997","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3389\/fimmu.2015.00644","article-title":"Dynamic Perturbations of the T-cell receptor repertoire in chronic HIV infection and following antiretroviral therapy","volume":"6","author":"Heather","year":"2015","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e83514","DOI":"10.1371\/journal.pone.0083514","article-title":"Dynamics of immune reconstitution and activation markers in HIV+ treatment-naive patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine","volume":"8","author":"Funderburg","year":"2013","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/imr.12064","article-title":"Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs","volume":"254","author":"Wilson","year":"2013","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1086\/597093","article-title":"Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment","volume":"48","author":"Kelley","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e25297","DOI":"10.1002\/jia2.25297","article-title":"Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study","volume":"22","author":"Castillo-Mancilla","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cei.12814","article-title":"Ageing and inflammation in patients with HIV infection","volume":"187","author":"Nasi","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/cncr.20354","article-title":"Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy","volume":"101","author":"Bonnet","year":"2004","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/fon.09.28","article-title":"Cancer risk in HIV-infected persons: influence of CD4+ count","volume":"5","author":"Clifford","year":"2009","journal-title":"Future Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s10552-018-1090-4","article-title":"Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men","volume":"29","author":"Dutta","year":"2018","journal-title":"Cancer Causes Control"},{"key":"B33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0190-9622(08)81978-0","article-title":"Idiopathic CD4+ T lymphocytopenia in a patient with mycosis fungoides","volume":"31","author":"Grossman","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/10428199609067597","article-title":"B Non-Hodgkin's Lymphoma in a Haemophilia Patient with Idiopathic CD4+ T-lymphocytopenia","volume":"21","author":"Paolini","year":"1996","journal-title":"Leuk Lymph"},{"key":"B35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?","volume":"7","author":"Menetrier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1001\/jamadermatol.2017.1716","article-title":"Association of multiple primary skin cancers with human immunodeficiency virus infection, CD4 count, and viral load","volume":"153","author":"Asgari","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/QAD.0000000000001018","article-title":"Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons","volume":"30","author":"Ryom","year":"2016","journal-title":"AIDS"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bulcan.2018.11.003","article-title":"Incidence of cancer in people living with HIV and prognostic value of current CD4","volume":"106","author":"Ebogo-Belobo","year":"2019","journal-title":"Bull Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/QAI.0000000000001394","article-title":"Association of CD4+ T-cell Count, HIV-1 RNA viral load, and antiretroviral therapy with kaposi sarcoma risk among HIV-infected persons in the United States and Canada","volume":"75","author":"Dubrow","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/jnci\/djx249","article-title":"Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma","volume":"110","author":"Shepherd","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/cid\/cix480","article-title":"Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: a multiregional multicohort study","volume":"65","author":"Rohner","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e85798","DOI":"10.1371\/journal.pone.0085798","article-title":"Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio","volume":"9","author":"Serrano-Villar","year":"2014","journal-title":"PLoS ONE."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog."},{"key":"B47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/COH.0000000000000326","article-title":"Lung cancer in persons with HIV","volume":"12","author":"igel","year":"2017","journal-title":"Curr Opin HIV AIDS."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1182\/blood-2009-02-204172","article-title":"Hodgkin lymphoma in the Swiss HIV cohort study","volume":"113","author":"Clifford","year":"2009","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0161594","DOI":"10.1371\/journal.pone.0161594","article-title":"Low CD4\/CD8 ratio is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco\/Copilote) prospective cohort study","volume":"11","author":"Hema","year":"2016","journal-title":"PLoS ONE."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/fimmu.2017.01215","article-title":"Coinhibitory receptor expression and immune checkpoint blockade: maintaining a balance in CD8(+) T cell responses to chronic viral infections and cancer","volume":"8","author":"Okoye","year":"2017","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"18023","DOI":"10.7448\/IAS.16.1.18023","article-title":"High-risk human papillomavirus infection in HIV-positive African women living in Europe","volume":"16","author":"Konopnicki","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"B52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2334-10-18","article-title":"Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers","volume":"10","author":"Luchters","year":"2010","journal-title":"BMC Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1097\/AOG.0b013e3181744619","article-title":"Squamous cervical lesions in women with human immunodeficiency virus","volume":"111","author":"Massad","year":"2008","journal-title":"Obstet Gynecol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nri3887","article-title":"The nature of immune responses to urinary tract infections","volume":"15","author":"Abraham","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1016\/j.vaccine.2018.09.059","article-title":"Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status","volume":"36","author":"Mugo","year":"2018","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e1004461","DOI":"10.1371\/journal.ppat.1004461","article-title":"Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity","volume":"10","author":"Scherer","year":"2014","journal-title":"PLoS Pathog."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"221ra13","DOI":"10.1126\/scitranslmed.3007323","article-title":"Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions","volume":"6","author":"Maldonado","year":"2014","journal-title":"Sci Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3389\/fimmu.2018.02569","article-title":"T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses","volume":"9","author":"Saeidi","year":"2018","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/QAD.0b013e3283601144","article-title":"Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection","volume":"27","author":"Unemori","year":"2013","journal-title":"AIDS."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3389\/fimmu.2018.02291","article-title":"Loss of T-cell multifunctionality and TCR-V\u03b2 repertoire against Epstein- Barr virus is associated with worse prognosis and clinical parameters in HIV+patients","volume":"9","author":"Hern\u00e1ndez","year":"2018","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"13128","DOI":"10.1038\/s41598-018-31572-6","article-title":"Molecular changes of lung malignancy in HIV infection","volume":"8","author":"Zheng","year":"2018","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.6004\/jnccn.2018.7064","article-title":"Evolving paradigms in HIV malignancies: review of ongoing clinical trials","volume":"16","author":"Bender Ignacio","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1002\/cncr.20309","article-title":"The changing pattern of Kaposi sarcoma in patients with HIV, 1994\u20132003: the EuroSIDA Study","volume":"100","author":"Mocroft","year":"2004","journal-title":"Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/sj.bjc.6604520","article-title":"Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy","volume":"99","author":"Franceschi","year":"2008","journal-title":"Brit J Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1200\/JCO.2005.04.156","article-title":"Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy","volume":"23","author":"Gallafent","year":"2005","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJM200004063421407","article-title":"Kaposi's sarcoma","volume":"342","author":"Antman","year":"2000","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/annonc\/mdx538","article-title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","author":"Heppt","year":"2017","journal-title":"Ann Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/annonc\/mdx817","article-title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","volume":"29","author":"Lavol\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"B71","volume-title":"Opdivo (nivolumab).","year":"2018"},{"key":"B72","volume-title":"Keytruda (pembrolizumab).","year":"2016"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: a phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1200\/JCO.2016.69.3812t","article-title":"Pomalidomide induces expansion of activated and central memory CD4+ and CD8+ T cells in vivo in patients with and without HIV infection","volume":"124","author":"Polizzotto","year":"2014","journal-title":"Blood"},{"key":"B75","volume-title":"Pomalyst (pomalidomide).","year":"2017"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/bloodadvances.2018024364","article-title":"Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv"},{"key":"B77","volume-title":"Adcetris (brentuximab vedotin).","year":"2014"},{"key":"B78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2055-6640(20)30694-4","article-title":"Alemtuzumab-induced elimination of HIV-1-infected immune cells","volume":"2","author":"Ruxrungtham","year":"2016","journal-title":"J Virus Erad"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1097\/QAD.0000000000001540","article-title":"Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome","volume":"31","author":"Rasmussen","year":"2017","journal-title":"AIDS"},{"key":"B80","volume-title":"Campath (alemtuzumab)","year":"2001"},{"key":"B81","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"B82","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nri2970","article-title":"Harnessing the biology of IL-7 for therapeutic application","volume":"11","author":"Mackall","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4049\/jimmunol.1601254","article-title":"Effect of IL-7 Therapy on phospho-ribosomal protein S6 and TRAF1 expression in HIV-specific CD8 T cells in patients receiving antiretroviral therapy","volume":"200","author":"Wang","year":"2018","journal-title":"J Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/QAD.0000000000001752","article-title":"HIV reservoir dynamics in HAART-treated poor immunological responder patients under IL-7 therapy","volume":"32","author":"Logerot","year":"2018","journal-title":"AIDS."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood.V97.10.2983","article-title":"A potential role for interleukin-7 in T-cell homeostasis","volume":"97","author":"Fry","year":"2001","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.virol.2006.02.019","article-title":"Interleukin-7 induces HIV replication in primary naive T cells through a nuclear factor of activated T cell (NFAT)-dependent pathway","volume":"350","author":"Managlia","year":"2006","journal-title":"Virology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1684\/ecn.2010.0205","article-title":"Interleukin-7 in HIV pathogenesis and therapy","volume":"21","author":"Chahroudi","year":"2010","journal-title":"Eur Cytokine Netw."},{"key":"B88","doi-asserted-by":"publisher","first-page":"96228","DOI":"10.1172\/jci.insight.96228","article-title":"IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion","volume":"2","author":"Le Saout","year":"2017"},{"key":"B89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cca.2010.09.002","article-title":"IL-7 and lymphopenia","volume":"412","author":"Ponchel","year":"2011","journal-title":"Clin Chim Acta"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20071681","article-title":"Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets","volume":"205","author":"Sport\u00e8s","year":"2008","journal-title":"J Exp Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jlb.55.2.280","article-title":"Interleukin-12","volume":"55","author":"Brunda","year":"1994","journal-title":"J Leukoc Biol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1182\/blood-2005-11-4455","article-title":"Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma","volume":"107","author":"Little","year":"2006","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cytogfr.2012.05.001","article-title":"The role of cytokines in the establishment, persistence and eradication of the HIV reservoir","volume":"23","author":"Vandergeeten","year":"2012"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.4049\/jimmunol.170.10.5018","article-title":"IL-15 promotes the survival of naive and memory phenotype CD8+ T cells","volume":"170","author":"Berard","year":"2003","journal-title":"J Immunol"},{"key":"B95","first-page":"219","article-title":"IL-15 in HIV infection: pathogenic or therapeutic potential?","volume":"21","author":"Mueller","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e00235","DOI":"10.1128\/JVI.00235-18","article-title":"Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo","volume":"92","author":"Garrido","year":"2018","journal-title":"J Virol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13578-016-0098-2","article-title":"IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia","volume":"6","author":"Xu","year":"2016"},{"key":"B98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/107999002753675712","article-title":"Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study","volume":"22","author":"Krown","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.1998.16.5.1736","article-title":"Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study","volume":"16","author":"Shepherd","year":"1998","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"812","DOI":"10.7326\/0003-4819-112-11-812","article-title":"Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)","volume":"112","author":"Krown","year":"1990","journal-title":"Ann Inten Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase i trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000001729","article-title":"Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma","volume":"32","author":"Rubinstein","year":"2018","journal-title":"AIDS"},{"key":"B107","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume":"7","author":"Sundar","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research HIV working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-017-0252-3","article-title":"Nivolumab as salvage treatment in a patient with HIV-related relapsed\/refractory Hodgkin lymphoma and liver failure with encephalopathy","volume":"5","author":"Sandoval-Sus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"737389","DOI":"10.1155\/2015\/737389","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis C and\/or HIV","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40425-018-0379-x","article-title":"Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection","volume":"6","author":"Husnain","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1200\/JCO.2011.36.9199","article-title":"Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma","volume":"29","author":"Burke","year":"2011","journal-title":"J ClinOncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS."},{"key":"B115","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/CJI.0000000000000240","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J Immunother"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.2019.37.15_suppl.2501","article-title":"Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected","volume":"37","author":"Gonz\u00e1lez-Cao","year":"2019","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"B122","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1073\/pnas.1522675113","article-title":"Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo","volume":"113","author":"Simonetti","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B124","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.1256304","article-title":"HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection","volume":"345","author":"Wagner","year":"2014","journal-title":"Science"},{"key":"B125","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","article-title":"HIV-1 integration in the human genome favors active genes and local hotspots","volume":"110","author":"Schr\u00f6der","year":"2002","journal-title":"Cell"},{"key":"B126","doi-asserted-by":"publisher","first-page":"99127","DOI":"10.1172\/jci.insight.99127","article-title":"HIV infection results in clonal expansions containing integrations within pathogenesis-related biological pathways","volume":"3","author":"Haworth","year":"2018","journal-title":"JCI insight"},{"key":"B127","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.1254194","article-title":"HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells","volume":"345","author":"Maldarelli","year":"2014","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"B129","first-page":"27","article-title":"Pembrozlizumab Induces HIV latency reversal in HIV+ Individuals on ART with Cancer","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Offersen","year":"2019"},{"key":"B130","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/annonc\/mdx321","article-title":"Nivolumab in HIV-related non-small-cell lung cancer","volume":"28","author":"Hentrich","year":"2017","journal-title":"Ann Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"E540","DOI":"10.21037\/jtd.2017.05.32","article-title":"Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer","volume":"9","author":"McCullar","year":"2017","journal-title":"J Thorac Dis"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","article-title":"Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab","volume":"31","author":"Le Garff","year":"2017","journal-title":"AIDS."},{"key":"B133","first-page":"61","article-title":"PD-1 blockade: a promising immunotherapy for HIV?","volume":"5","author":"Macatangay","year":"2009","journal-title":"Cell Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"key":"B136","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e0198158","DOI":"10.1371\/journal.pone.0198158","article-title":"An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients","volume":"13","author":"Colston","year":"2018","journal-title":"PLoS ONE"},{"key":"B139","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/1074-7613(95)90003-9","article-title":"Cross-linking of CD30 induces HIV expression in chronically infected T cells","volume":"2","author":"Biswas","year":"1995","journal-title":"Immunity."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e1006856","DOI":"10.1371\/journal.ppat.1006856","article-title":"Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30","volume":"14","author":"Hogan","year":"2018","journal-title":"PLoS Pathog."},{"key":"B141","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1182\/blood-2010-12-323600","article-title":"Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance","volume":"118","author":"Hodge","year":"2011","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/cid\/cis383","article-title":"Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I\/IIa randomized, placebo-controlled, multicenter study","volume":"55","author":"L\u00e9vy","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood-2002-07-1957","article-title":"IL-15 enhances survival and function of HIV-specific CD8+ T cells","volume":"101","author":"Mueller","year":"2003","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/107999000312513","article-title":"Effects of interleukin-15 on in vitro human T cell proliferation and activation","volume":"20","author":"Hasan","year":"2000","journal-title":"J Interferon Cytokine Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1100\/tsw.2011.102","article-title":"Eradication of HIV by transplantation of CCR5-deficient hematopoietic stem cells","volume":"11","author":"Hutter","year":"2011","journal-title":"Sci World J."},{"key":"B148","doi-asserted-by":"publisher","first-page":"674","DOI":"10.7326\/M18-0759","article-title":"Mechanisms that contribute to a profound reduction of the HIV-1 reservoir after allogeneic stem cell transplant","volume":"169","author":"Salgado","year":"2018","journal-title":"Ann Intern Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases","volume":"161","author":"Henrich","year":"2014","journal-title":"Ann Intern Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jgm.705","article-title":"Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients","volume":"7","author":"Macpherson","year":"2005","journal-title":"J Gene Med"},{"key":"B151","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nm.1932","article-title":"Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells","volume":"15","author":"Mitsuyasu","year":"2009","journal-title":"Nat Med"},{"key":"B152","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.coi.2012.08.013","article-title":"Creating genetic resistance to HIV","volume":"24","author":"Burnett","year":"2012","journal-title":"Curr Opin Immunol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.it.2012.07.001","article-title":"Developing strategies for HIV-1 eradication","volume":"33","author":"Durand","year":"2012","journal-title":"Trends Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1200\/JCO.2007.14.5532","article-title":"Including persons with HIV infection in cancer clinical trials","volume":"26","author":"Persad","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T09:27:58Z","timestamp":1610875678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":154,"alternative-id":["10.3389\/fimmu.2019.02060"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02060","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"article-number":"2060"}}